---
layout: post
title: "Sage Therapeutics, Inc.; Withdrawal of Approval of a New Drug Application for ZULRESSO (Brexanolone) Solution, 100 Milligrams/20 Milliliters"
date: 2026-02-04 21:50:34 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2025-04101
original_published: 2025-03-14 00:00:00 +0000
significance: 8.00
---

# Sage Therapeutics, Inc.; Withdrawal of Approval of a New Drug Application for ZULRESSO (Brexanolone) Solution, 100 Milligrams/20 Milliliters

**Published:** February 04, 2026 21:50 UTC
**Source:** Federal Register
**Original Published:** March 14, 2025 00:00 UTC
**Document Number:** 2025-04101

## Summary

The Food and Drug Administration (FDA or Agency) is withdrawing approval of a new drug application (NDA) for ZULRESSO (brexanolone) solution, 100 milligrams (mg)/20 milliliters (mL), held by Sage Therapeutics, Inc., 55 Cambridge Parkway, Cambridge, MA 02142 (Sage). Sage notified the Agency in writing that the drug product was no longer marketed and requested that the approval of the application be withdrawn.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2025/03/14/2025-04101/sage-therapeutics-inc-withdrawal-of-approval-of-a-new-drug-application-for-zulresso-brexanolone)
- API: https://www.federalregister.gov/api/v1/documents/2025-04101

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
